The rise of virtual and hybrid pharmaceutical companies — those that outsource all or part of their GXP operations — continues to reshape the landscape of modern drug development. While outsourcing offers strategic flexibility and financial efficiency, it does not absolve sponsor companies of regulatory accountability. Regulatory authorities hold sponsors to the same rigorous standards as fully integrated organizations, viewing contracted entities as direct extensions of the sponsor. These innovation-driven companies depend heavily on external partners such as Contract Manufacturing Organizations (CMOs), Contract Development and Manufacturing Organizations (CDMOs), and Contract Research Organizations (CROs) to execute critical GXP activities. However, this model introduces complex quality oversight obligations that are sometimes underestimated or insufficiently prioritized without the right partner and insights.
This white paper explores the key compliance challenges associated with virtual and hybrid operational models and offers best practice recommendations to help sponsors maintain robust oversight of their outsourced vendors.
Julie Barnhill, PhD | Senior Consultant